Burns J W & Co. Inc. NY Sells 15,154 Shares of Pfizer Inc. (NYSE:PFE)

Burns J W & Co. Inc. NY lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 21.8% during the first quarter, Holdings Channel.com reports. The firm owned 54,405 shares of the biopharmaceutical company’s stock after selling 15,154 shares during the quarter. Burns J W & Co. Inc. NY’s holdings in Pfizer were worth $1,510,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. GoalVest Advisory LLC grew its position in shares of Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares in the last quarter. Creekmur Asset Management LLC acquired a new stake in Pfizer during the fourth quarter worth approximately $32,000. VisionPoint Advisory Group LLC increased its stake in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the period. Tennessee Valley Asset Management Partners acquired a new position in Pfizer in the 4th quarter valued at $36,000. Finally, DiNuzzo Private Wealth Inc. bought a new stake in shares of Pfizer during the 4th quarter valued at $37,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday. Morgan Stanley boosted their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Nine analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus price target of $35.54.

Pfizer Trading Up 0.6 %

NYSE PFE opened at $27.98 on Friday. The company has a market cap of $158.55 billion, a price-to-earnings ratio of -466.26, a price-to-earnings-growth ratio of 1.10 and a beta of 0.70. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $37.80. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. The business’s fifty day moving average is $27.90 and its 200 day moving average is $27.68.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same period last year, the firm posted $1.23 earnings per share. The business’s revenue for the quarter was down 19.5% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.00%. The ex-dividend date of this dividend is Thursday, July 25th. Pfizer’s dividend payout ratio (DPR) is currently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.